Synthesis and structure - Activity relationships of carboxyflavones as structurally rigid CysLT1 (LTD4) receptor antagonists

Journal of Medicinal Chemistry

Volumn 41, Issue 9, 1998, Pages 1428-1438

  Zwaagstra, Mariël E ^a   Timmerman, Henk ^a   Van de Stolpe, Andrea C ^a   De Kanter, Frans J J ^a   Tamura, Masahiro ^b   Wada, Yasushi ^b   Zhang, Ming Qiang ^a,c  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b KOWA COMPANY LTD   (Japan)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 CARBOXY 3' [2 (2 QUINOLINYL)ETHENYL]FLAVONE; 8 CARBOXY 6 CHLORO 3' (2 QUINOLINYLMETHOXY)FLAVONE; CARBOXYFLAVONE DERIVATIVE; FLAVONE DERIVATIVE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; ASTHMA; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; GUINEA PIG; INFLAMMATION; NONHUMAN; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-ASTHMATIC AGENTS; FLAVONOIDS; GUINEA PIGS; ILEUM; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENE D4; LUNG; MALE; MEMBRANE PROTEINS; MUSCLE CONTRACTION; MUSCLE, SMOOTH; QUINOLINES; RECEPTORS, LEUKOTRIENE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032560231     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970179x     Document Type: Article

References (57)

1. Mayatepek, E.; Hoffmann, G. F. Leukotrienes: Biosynthesis, metabolism, and pathophysiologic significance. Pediatric Res. 1995, 37, 1-9.
2. Chung, K. F. Leukotriene receptor antagonists and biosynthesis inhibitors: Potential breakthrough in asthma therapy. Eur. Respir. J. 1995, 8, 1203-1213.
3. Thien, F. C. K.; Walters, E. H. Eicosanoids and asthma: an update. Prostaglandins Leukotrienes Essent. Fatty Acids 1995, 52, 271-288.
4. Denzlinger, C.; Haberl, C.; Wilmanns, W. Cysteinyl leukotriene production in anaphylactic reactions. Int. Arch. Allergy Immunol. 1995, 108, 158-164.
5. Chanarin, N.; Johnston, S. L. Leukotrienes as a target in asthma therapy. Drugs 1994, 47, 12-24.
6. Pauwels, R. A.; Joos, G. F.; Kips, J. C. Leukotrienes as therapeutic target in asthma. Allergy 1995, 30, 615-622.
7. Hay, D. W. P.; Torphy, T. J.; Undem, B. J. Cysteinyl leukotrienes in asthma: Old mediators up to new tricks. Trends Pharmacol. Sci. 1995, 16, 304-309.
8. Henderson, J. W. R. The role of leukotrienes in inflammation. Ann. Intern. Med. 1994, 121, 684-697.
9. 2 receptors. For a review of leukotriene receptors, see: Metters, K. M. Leukotriene receptors. J. Lipid Mediat. Cell Signal. 1995, 12, 413-427.
10. Samuelsson, B. Leukotrienes: Mediators of immediate hyper-sensitivity reactions and inflammation. Science 1983, 220, 568-575.
11. Sprecher, V. A.; Beck, A.; Gerspacher, M.; Bray, M. A. Peptidoleukotriene antagonists: state of the art. Chimia 1992, 46, 304-311.
12. Brooks, C. D. W.; Summers, J. B. Modulators of leukotriene biosynthesis and receptor activation. J. Med. Chem. 1996, 39, 2629-2654.
13. Harris, R. R.; Carter, G. W.; Bell, R. L.; Moore, J. L.; Brooks, D. W. Clinical activity of leukotriene inhibitors. Int. J. Immunopharmacol. 1995, 17, 147-156.
14. Drazen, J. M.; Israel, E. Treatment of chronic stable asthma with drugs active on the 5-lipoxygenase pathway. Int. Arch. Allergy Immunol. 1995, 707, 319-320.
15. Drazen, J. Clinical studies with agents active on the 5-lipoxy-genase pathway. Allergy 1995, 50, 22-26.
16. Gillard, J. W.; Guindon, Y. The leukotrienes: Prospects for therapy against a unique family of pathophysiological mediators. Drugs Future 1987, 12, 453-474.
17. Taylor, I. K. Cysteinyl leukotrienes in asthma: Current state of therapeutic evaluation. Thorax 1995, 50, 1005-1010.
18. Marshall, W. S.; Goodson, T.; Cullinan, G. J.; Swanson-Bean, D.; Haisch, K. D.; Rinkema, L. E.; Fleisch, J. H. Leukotriene receptor antagonists 1. Synthesis and structure-activity relationships of alkoxyacetophenone derivatives. J. Med. Chem. 1987, 30, 682-689.
19. Hay, D. W. P. SK&F 104353 2(S)-Hydroxy-3(R)-(2-carboxyethylthio)-3-[2-(8-phenyloctyl)phenyl]propanoic acid. Drugs Future 1990, 15, 240-244.
20. Gleason, J. G.; Hall, R. F.; Perchonock, C. D.; Erhard, K. F.; Frazee, J. S.; Ku, T. W.; Kondrad, K.; McCarthy, M. E.; Mong, S.; Crooke, S. T.; Chi-Rosso, G.; Wasserman, M. A.; Torphy, T. J.; Muccitelli, R. M.; Hay, D. W.; Tucker, S. S.; Vickery-Clark, L. High-affinity leukotriene receptor antagonists. Synthesis and pharmacological characterization of 2-hydroxy-3-[(2-carboxyethyl)thio]-3-[2-(8-phenyloctyl)phenyl]propanoic acid. J. Med. Chem. 1987, 30, 959-961.
21. Perchonock, C. D.; Uzinskas, I.; McCarthy, M. E.; Erhard, K. F.; Gleason, J. G.; Wasserman, M. A.; Muccitelli, R. M.; DeVan, J. F.; Tucker, S. S.; Vickery, L. M.; Kirchner, T.; Weichman, B. M.; Mong, S.; Scott, M. O.; Chi-Rosso, G.; Wu, H. J.; Crooke, S. T.; Newton, J. F. Synthesis and structure-activity relationship studies of a series of 5-aryl-4,6-dithianonanedioic acids and related compounds: A novel class of leukotriene antagonists. J. Med. Chem. 1986, 29, 1442-1452.
22. 4) receptor antagonists. J. Med. Chem. 1992, 35, 1191-1200.
23. Baker, S. R.; Boot, J. R.; Wishart, G. Sulukast (LY-170680): Leukotriene D4/E4 antagonist. Drugs Future 1991, 16, 432-436.
24. Abram, T. S.; Boshagen, H.; Futler, J. E.; Cuthbert, N. J.; Francis, H. P.; Gardiner, P. F.; Hartwig, W.; Kluender, H. C.; Norman, P.; Meier, H.; Rosentreter, U.; Schlemmer, K. H.; Tudhope, S. R.; Taylor, W. A. A new structural analogue antagonist of peptide leukotrienes. The discovery of BAY x7195. Bioorg. Med. Chem. Lett. 1993, 3, 1517-1522.
25. 4 antagonist activity of bicyclic and monocyclic cyclopentylurethane and cyclopentylacetamide N-arylsulfonyl amides. J. Med. Chem. 1990, 33, 2621-2629.
26. Yee, Y. K.; Bernstein, P. R.; Adams, E. J.; Brown, F. J.; Cronk, L. A.; Hebbel, K. C.; Vacek, E. P.; Krell, R. D.; Snyder, D. W. A novel series of selective leukotriene antagonists: Exploration and optimization of the acidic region in 1,6-disubstituted indoles and indazoles. J. Med. Chem. 1990, 33, 2437-2451.
27. Brown, F. J.; Yee, Y. K.; Cronk, L. A.; Hebbel, K. C.; Krell, R. D.; Snyder, D. W. Evolution of a series of peptidoleukotriene antagonists: Synthesis and structure-activity relationships of 1,6-disubstituted indoles and indazoles. J. Med. Chem. 1990, 33, 1771-1781.
28. Jacobs, R. T.; Brown, F. J.; Cronk, L. A.; Aharony, D.; Buckner, C. K.; Kusner, E. J.; Kirkland, K. M.; Neilson, K. L. Substituted 3-(Phenylmethyl)-lH-indole-5-carboxamides and l-(Phenylmethyl)indole-6-carboxamides as potent, selective, orally active antagonists of the peptidoleukotrienes. J. Med. Chem. 1993, 36, 394-409.
29. Brown, F. J. In The Search for Antiinflammatory Drugs. Case Histories from Concept to Clinic; Merluzi, V. J., Adams, J., Eds.; Birkhauser: Boston, 1995; pp 161-189.
30. Toda, M.; Nakai, H.; Kosuge, S.; Konno, M.; Arai, Y.; Miyamoto, T.; Obata, T.; Katsube, N.; Kawasaki, A. A potent antagonist of the slow-reacting substance of anaphylaxis. Adv. Prostaglandin Thromboxane Leukotriene Res. 1985, 15, 307-308.
31. Nakai, H.; Konno, M.; Kosuge, S.; Sakuyama, S.; Toda, M.; Arai, Y.; Obata, T.; Katsube, N.; Miyamoto, T.; Okegawa, T.; Kawasaki, A. New potent antagonists of leukotrienes C4 and D4. 1. Synthesis and structure-activity relationships. J. Med. Chem. 1988, 31, 84-91.
32. Yamada, N.; Yamada, K.; Takahashi, K.; Nakao, E.; Kadowaki, S.; Umezu, K. Pharmacological profile of the novel, potent and selective peptide leukotriene antagonist (E)-2,2-Diethyl-3′-[2-[2-(4-isopropyl;thiazolyl]ethenyl]siccinanilic acid. Arzneim.-Forsch. / Drug Res. 1994, 44, 749-753.
33. 4. J. Pharmacol. Exp. Ther. 1991, 259, 751-758.
34. 4 receptor binding affinity. J. Med. Chem. 1991, 34, 1704-1707.
35. 4 receptor antagonist devoid of peroxisomal enzyme induction. Bioorg. Med. Chem. Lett. 1995, 5, 283-288.
36. Sprecher, V. A.; Beck, A.; Gerspacher, M.; Sallmann, A.; Anderson, G. P.; Subramanian, N.; Niederhauser, U.; Bray, M. A. Strategies in the design of peptidoleukotriene antagonists. J. Lipid Mediators 1993, 6, 265-273.
37. 4 antagonists. Drugs Future 1988, 13, 745-759.
38. Terada, H.; Goto, S.; Hori, H.; Taira, Z. In QSAR and Drug Design - New Developments and Applications; Fujita, T., Ed.; 1995; pp 341-367.
39. Palomer, A.; Giolitti, A.; Garcia, M. L.; Fos, E.; Cabre, F.; Mauleon, D.; Carganico, G. In QSAR and Molecular Modelling: Concepts, Computational Tools and Biological Applications; Sanz, F., Giraldo, J., Manaut, F., Eds.; Prous Science Publishers: Barcelona, 1995; pp 444-450.
40. Hermann, R. B.; Herron, D. K. OVID and SUPER: Two overlap programs for drug design. J. Comput. -Aided. Mol. Des. 1991, 5, 511-524.
41. 4. J. Med. Chem. 1995, 38, 2472-2477.
42. 4 antagonists. Eur. J. Med. Chem. 1996, 31, 861-874.
43. 1 (LTD4) receptor antagonists. J. Med. Chem. 1997, 40, 1075-1089.
44. Emilewicz, T; Kostanecki, V. S. Chem. Ber. 1898, 31, 696.
45. Pfister, J. R. Neue 1,4-Benzopyron-6-carbonsauren und Verfahren zu ihrer Herstellung und Verwendung. Ger. Offen. C 07 D 311.30, Apr. 17, 1975.
46. Matsumura, H.; Tsuchiya, T.; Takeda, T.; Imafuku, K. Synthesis of 6- and 8-phenyl-substituted flavonoids. Bull. Chem. Soc. Jpn. 1983, 56, 2037-2043.
47. Awad, W. I.; El-Neweihy, M. F.; Selim, S. F. Studies on 3-acylcatechols. II. A new synthesis of 8-hydroxyflavone. Chem. Ind. 1960, 25, 1333-1336.
48. Makrandi, J. K. An efficient procedure for cyclisation of 2′-hydroxychalcones into flavones. Chem. Ind. 1989, 607.
49. Hsu, K. K.; Chang, S. F. Synthesis of 2-(2-quinoxalyl) chromone derivatives. Taiwan K'o Hsuch 1976, 30, 146-52.
50. Shanker, C. G.; Mallaiah, B. V.; Srimannarayana, G. Dehydrogenation of chromanones and flavanones by DDQ: A facile method for the synthesis of chromones and flavones. Synthesis 1983, 310-311.
51. Imafuku, K.; Honda, M.; McOmie, J. F. W. Cyclodehydrogenation of 2′-hydroxychalcones with DDQ: A simple route for flavones and aurones. Synthesis 1987, 199-201.
52. Baker, W. Molecular rearrangement of some o-acyloxyacetophenones and the mechanism of the production of 3-acylchromones. J. Chem. Soc. 1933, 1381-1389.
53. Wu, E. S. C.; Cole, T. E.; Davidson, T. A.; Dailey, M. A.; Doring, K. G.; Fedorchuk, M.; Loch, J. T.; Thomas, T. L.; Blosser, F. C.; Borrelli, A. R.; Kinsolving, C. R.; Parker, R. B.; Strand, J. C.; Watkins, B. E. Flavones. 2. Synthesis and structure-activity relationship of flavodilol and its analogues, a novel class of antihypertensive agents with catecholamine depleting properties. J. Med. Chem. 1989, 32, 183-192.
54. Erickson, R. H.; Natalie, K. J., Jr.; Bock, W.; Lu, Z.; Farzin, F.; Sherill, R. G.; Meloni, D. J.; Patch, R. J.; Rzesotarski, W. J.; Clifton, J.; Pontecorvo, M. J.; Bailey, M. A.; Naper, K.; Karbon, W. (Aminoalkoxy)chromones. Selective s-receptor ligands. J. Med. Chem. 1992, 35, 1526-1535.
55. Ares, J. J.; Outt, P. E.; Kakodkar, S. V.; Buss, R. C.; Geiger, J. C. A convenient large-scale synthesis of 5-methoxyflavone and its application to analog preparation. J. Org. Chem. 1993, 58, 7903-7905.
56. Doria, G.; Romeo, C.; Giraldi, P.; Lauria, F.; Sberze, P.; Tibolla, M.; Corno, M. L.; Cadelli, G.; Montoro, C. Antiallergic agents. I. Substituted 4-oxo-4H-1-benzopyran-6-carboxylic acids. Ear. J. Med. Chem.-Chim. Ther. 1978, 13, 33-39.
57. 4) antagonist model with an incorporated amino acid residue from the receptor. J. Med. Chem. 1998, 41, 1439-1445.